Table 1.
Characteristics of 114 included studies
| Characteristic | No (%) |
|---|---|
| Journal | |
| Annals of Internal Medicine | 2 (2) |
| Circulation | 45 (39) |
| European Heart Journal | 17 (15) |
| JAMA | 21 (18) |
| Lancet | 21 (18) |
| New England Journal of Medicine | 8 (7) |
| Cardiovascular area | |
| Coronary disease | 91 (80) |
| Heart failure | 12 (11) |
| Vascular disease | 9 (8) |
| Other* | 2 (2) |
| Intervention | |
| Drug | 76 (67) |
| Coronary intervention (surgery/percutaneous) | 13 (11) |
| Vascular intervention (surgery/percutaneous) | 2 (2) |
| Other† | 23 (20) |
| No of composite end points per trial (n=111) | |
| 1 | 65 (59) |
| 2 | 28 (25) |
| 3 | 12 (11) |
| ≥4 | 6 (5) |
| Total No of components per composite end point | |
| 2 | 39 (34) |
| 3 | 44 (39) |
| 4 | 14 (12) |
| >4 | 17 (15) |
| Effect on components reported | |
| Every component | 77 (68) |
| Some components | 21 (18) |
| No components | 16 (14) |
*Valvular heart disease, primary cardiovascular prevention, arrhythmia, or cardiomyopathy.
†Rehabilitation or lifestyle intervention (diet, daily activity).